CG
ADAP

Cutler Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Cutler Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-28,100
Closed -$36K – 4597
2020
Q2 		$36K Buy
+28,100
New +$176K ﹤0.01% 1967
2018
Q2 		– Sell
-1,100
Closed -$3K – 4115
2018
Q1 		$3K Buy
+1,100
New +$9.63K ﹤0.01% 3509

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's ADAP Position: Q1 2024 in Review

Cutler Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2024, closing a stake of 1,400 shares — an estimated $1K sold.

Cutler Group first reported a position in ADAP in Q3 2017 and held it in 21 quarters. The position peaked at $71K in Q3 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2024.

  • Cutler Group reported no remaining Adaptimmune Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,400 Adaptimmune Therapeutics shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 21 quarters.
  • Cutler Group's Adaptimmune Therapeutics position peaked at $71K in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.